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The Multiple Roles of PTEN Minireview
in Tumor Suppression
missense mutations in PTEN detected in primary tumors
and in cell lines are confined to exon 5, which encodes
this domain. Despite its homology with dual-specificity
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Memorial Sloan-Kettering Cancer Center phosphatases, PTEN is an inefficient protein phospha-
tase in vitro; however, it is very active on highly acidicSloan-Kettering Institute
New York, New York 10021 substrates. This finding suggested that the substrates of
PTEN might not be proteins. In fact, phosphatidylinositol
(3,4,5)-triphosphate (PIP-3) has proved to be the main
PTEN substrate: PTEN specifically cleaves, in vitro andIn his celebrated monolog, the Shakespearean hero
in vivo, the D3 phosphate of this second messengerHamlet clearly identified two extreme remedies: ªTo die:
lipid produced by the activity of PI3-kinase (Maehamato sleep; no moreº against ªthe heartache and the thou-
and Dixon, 1998). Solving the crystal structure of PTENsand natural shocks....º The same two functions: induc-
has elucidated the structural basis for this unexpectedtion of programmed cell death (ªto dieº) and cell cycle
catalytic property. In PTEN, unlike other DSPs, one ofarrest (ªto sleepº), are essential in order to antagonize
the loops embracing the catalytic site has a four-residuethe genetic insults that underlie the genesis of cancer
insertion, resulting in a wider pocket, which accommo-at the cellular level. However, in the case of the protein/
dates PIP-3 (Lee et al., 1999). The crystallographic datalipid phosphatase PTEN, the most highly mutated tu-
also uncovered a second distinctive feature in the PTENmor-suppressor gene in the post-p53 era, a lot more is
structure: the catalytic site is surrounded by three posi-emerging. It is now becoming clear that PTEN plays a
tively charged amino acids (Lys-125, Lys-128, and His-significant role not only in inducing cell cycle arrest and
93), which accounts for the known preference of PTENprogramming apoptosis, but also in other aspects of
for highly acidic substrates.cell physiology, including the regulation of cell adhesion,
The catalytic pocket of PTEN is deep and wide enoughmigration, and differentiation.
to accommodate phosphotyrosine or a phosphoserine/The PTEN (phosphatase and tensin homolog deleted
threonine residue, so PTEN might be able to act onfrom chromosome 10) tumor-suppressor gene, also
protein substrates as well. Interestingly, recent studiesknown as MMAC1 (mutated in multiple advanced cancers)
suggest that focal adhesion kinase (FAK) and Shc mayor TEP1 (TGFb-regulated and epithelial cell±enriched
be regulated by PTEN (see below) (Tamura et al., 1999phosphatase), is located on chromosome 10q23, a ge-
and references therein). However, it is important to notenomic region that suffers loss of heterozygosity (LOH)
that the tumor-suppressive function of PTEN is depen-in many human cancers (reviewed in Cantley and Neel,
dent only on its lipid phosphatase activity (Myers et al.,1999). Somatic deletions or mutations of this gene have
1998).been identified in a large fraction of tumors, including
Apoptosis and Cell Cycle Controlglioblastomas and endometrial and advanced prostate
The discovery that PIP-3 is the main in vivo substratecancers, thus placing PTEN among the most commonly
of PTEN immediately placed this phosphatase into amutated genes in human cancer.
well-defined pathway (Figure 1). PIP-3 levels are veryGermline PTEN mutations have been detected in more
low in quiescent cells, but rapidly increase upon stimula-than 80% of patients with one of three related autosomal
tion by growth factors, through activation of PI3-kinase.dominant disorders: Cowden disease (CD), Lhermitte-
Accumulation of PIP-3 at the membrane allows recruit-Duclos disease (LDD), and Bannayan-Zonana syndrome
ment of proteins containing a pleckstrin homology (PH)(BZS) (Liaw et al., 1997). These syndromes share specific
domain, which binds PIP-3. One of these proteins isdevelopmental defects as well as similar pathological
the proto-oncogene serine/threonine kinase Akt (alsofeatures such as multiple benign tumors (mostly hamar-
known as PKB). Upon membrane recruitment, Akt istomas), and an increased susceptibility to breast and
activated by phosphorylation. Activated Akt is a well-thyroid malignancies. Mice heterozygous for Pten-inac-
established survival factor, exerting antiapoptotic activ-tivating mutations also display hyperplastic-dysplastic
ity by preventing the release of cytochrome c from mito-features and a high incidence of spontaneous tumors of
chondria and inactivating Forkhead transcription factorsvarious histological origins. These findings demonstrate
(FKHR), which are known to induce the expression ofthe critical role of PTEN in tumor suppression (Di Cristo-
genes that are critical for apoptosis. Moreover, Aktfano et al., 1998; Suzuki et al., 1998; Podsypanina et al.,
phosphorylates and inactivates the proapoptotic factor1999).
BAD and caspase-9, although caspase-9 appears to beAn Elusive Phosphatase
an Akt substrate only in human cells (Datta et al., 1999).PTEN contains a protein tyrosine phosphatase (PTP)
In this context, the role of PTEN is to keep the levels ofdomain with features resembling those of the ªdual-
PIP-3 low. Loss of PTEN function results in an increasedspecificityº phosphatases (DSPs), which are able to
concentration of PIP-3 and in Akt hyperactivation, lead-dephosphorylate both tyrosine and serine/threonine
ing to protection from various apoptotic stimuli (Stam-residues. The functional importance of the PTEN phos-
bolic et al., 1998). Surprisingly, even the inactivation ofphatase domain is underscored by the fact that most
just one Pten allele has a dramatic impact on the survival
and proliferation of selected cell populations such as* To whom correspondence should be addressed (e-mail: p-pandolfi@
ski.mskcc.org). lymphocytes, at least in a mouse model (Di Cristofano
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Figure 1. Role of PTEN in the Control of Cell
Death and Proliferation
Activation of PI3-kinase by growth factor- or
extracellular matrix (ECM)-dependent signal-
ing leads to synthesis of PIP-3 that is dephos-
phorylated by PTEN to phosphatidylinositol
(4,5)-diphosphate (PIP-2). Akt binding to
PIP-3 allows its phosphorylation and activa-
tion. In the absence of PTEN, activated Akt
phosphorylates and inactivates members of
the Forkhead family of transcription factors
(FKHR), the proapoptotic proteins Bad and
caspase-9, and blocks cytochrome c release
and Fas-dependent apoptosis through still
unknown pathways. This results in cellular
protection from several apoptotic stimuli. Ac-
tivated Akt also downregulates p27 levels and
inactivates Gsk-3, resulting in stabilization of
cyclin D1, thus leading to increased cellular
proliferation. PTEN might interact with and
dephosphorylate FAK and Shc, thus possibly
inhibiting cell spreading and motility through
downregulation of focal adhesion and MAP
kinase signals.
et al., 1999). Pten1/2 mutants developed a lethal autoim- the inhibition of Rb phosphorylation (Lu et al., 1999).
Consistent with these observations, p27 protein levelsmune syndrome with features reminiscent of those ob-
served in Fas-deficient mutants. In addition, Pten1/2 were reduced in Pten2/2 ES cells (Sun et al., 1999). The
effects of PTEN on the levels of p27 appear to be depen-mice and cells showed impaired Fas-dependent apo-
ptosis that could be restored by PI3-kinase inhibitors. dent on suppression of the PI-3 kinase/Akt pathway, as
PI-3 kinase inhibitors such as wortmannin and LY294002These findings established a genetic link between the
Fas proapoptotic pathway and the antiapoptotic role of could mimic the effects of PTEN on both the cell cycle
and p27 protein levels. Moreover, coexpression of PTENPI3-kinase/Akt antagonized, in turn, by PTEN, and also
suggested a possible role for PTEN in the pathogenesis with activated PI3-kinase or Akt efficiently antagonized
PTEN-mediated growth suppression (Paramio et al.,of autoimmune disorders.
Overexpression of PTEN in glioma and breast cancer 1999). A further link between PTEN and the Rb pathway
is suggested by the observation that PTEN does notcells results in the inactivation of Akt and the induction
of anoikis, a specific apoptotic pathway initiated by cell induce G1 arrest in the Rb2/2 Saos-2 or C33A cells un-
less Rb is cotransfected (Paramio et al., 1999).detachment from the extracellular matrix. This effect
can be mimicked by inhibition of PI3-kinase signaling However, in some PTEN1/1 cancer cell lines such as
the glioblastoma cell line LN229, the overexpression of(Lu et al., 1999; Tamura et al., 1999). Thus, PTEN controls
cell death upon loss of contact with the extracellular PTEN does not cause G1 arrest. In view of the correlation
between PTEN expression, p27 upregulation, and Rbmatrix by inhibiting PI3-kinase-dependent survival sig-
nals. The role of PTEN in the control of anoikis is particu- activation, the apparent contradictions concerning the
ability of PTEN to induce G1 arrest in PTEN1/1 cellslarly relevant because PTEN mutations are often associ-
ated with an aggressive metastatic tumor phenotype. might depend on the functional status of components
of the Rb pathway in these cells.The fact that PTEN regulates Akt function may explain
its tumor suppressive role through control of cell sur- PTEN inactivation might also result in increased cell
cycle progression through the Akt-dependent phos-vival. However, whether PTEN also plays a role in the
control of cell cycle remained to be tested. Synchroniza- phorylation and inactivation of glycogen synthase ki-
nase-3 (GSK-3), which, in turn, leads to cyclin D1 stabili-tion of embryonic stem (ES) cells using a mitotic shake-
off method revealed a slight shortening (5%±10%) of zation (Figure 1). In agreement with this notion, reduced
levels of cyclyn D1 are observed upon PTEN overexpres-the cell cycle length in Pten2/2 cells, although no such
difference was seen in mouse embryonic fibroblasts or sion in C33A cells (Paramio et al., 1999).
An additional question relates to why reintroductionin asynchronous ES cells cultures (Di Cristofano et al.,
1998; Sun et al., 1999). of PTEN into different tumor cell lines results in either cell
cycle arrest (glioblastoma, renal carcinoma cell lines) orOverexpression of PTEN in a variety of cancer cell
lines has allowed better definition of its role in the control apoptosis (prostate carcinoma cell lines). Although it is
possible that the tumor-suppressive consequences ofof cell cycle and tumor suppression, in spite of seem-
ingly contradictory data. In the absence of external PTEN reexpression depend solely on the cell type from
which the tumor originates, the behavior of PTEN couldapoptotic stimuli and in the presence of growth factors,
restoration of wild-type PTEN in several PTEN2/2 cell well be influenced by the other oncogenic pathways
that are deregulated during neoplastic transformation.lines, including glioblastoma and breast and renal carci-
noma, invariably resulted in G1 arrest as early as 24 hr However, recent data show that the effects of PTEN
overexpression also change if analyzed at different timeafter infection (Lu et al., 1999). This G1 arrest correlated
with posttranscriptional upregulation of p27 protein, its points or in different culture conditions (Lu et al., 1999;
Weng et al., 1999). For example, restoration of PTENassociation with cyclin E/CDK2 complexes, and with
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activity in breast cancer cells results in early G1 arrest, tumors, the samples were prescreened for LOH at
10q23, and then analyzed for mutations in the remainingfollowed by apoptosis. It is noteworthy that in the reports
describing apoptotic responses upon PTEN overexpres- allele. The results showed that LOH at 10q23 is a very
common event in most primary tumors (25%±50%), butsion in prostate carcinoma cells, cell death was only
detected four days after adenoviral infection, and it the complete loss of PTEN function in early stage tumors
occurs only in endometrial and ovarian cancer. In mostcould not completely account for the significant growth
inhibition observed (Davies et al., 1999). Moreover, in other cases, including glioblastoma and prostate carci-
noma, complete inactivation of PTEN is associated withthe absence of serum, and thus in conditions in which
the cells are already arrested in G1 arrest, PTEN readily late-stage, more aggressive, and usually metastatic tu-
mors. In view of these findings, and as complete lossinduces apoptosis in breast cancer cells (Lu et al., 1999).
These findings can be reconciled in a unifying model of PTEN is common in tumor cell lines, loss of this gene
has been regarded a late event in the transformationin which, in the absence of direct external apoptotic
stimuli (i.e., cell detachment, Fas), PTEN exerts its tumor process.
However, the fact that the inactivation of just one Ptensuppressive role initially through induction of G1 arrest.
In such a model, apoptosis would follow PTEN-induced allele has an important consequence on cell survival
and proliferation in a mouse model (Di Cristofano et al.,G1 arrest as a consequence of the PTEN-mediated inhi-
bition of the growth factor±dependent survival signals. 1999), suggests that the picture may be more complex.
If the mutation of only one allele of PTEN can result inThe extent and kinetics of PTEN-induced programmed
cell death would then depend on the levels of trophic impaired apoptosis and growth advantage, then the role
played by the loss of one PTEN allele in the early patho-support.
Adhesion-Dependent Signaling genesis of many human tumors might have been under-
estimated. PTEN haploinsufficiency could be an impor-The possible involvement of PTEN in the regulation of
cell adhesion and migration could provide a rationale tant factor in early selection and expansion of cells
during transformation. At later stages in tumor progres-for the frequent loss of the gene observed in late-stage
metastatic tumors. It has been reported that reintroduc- sion, complete loss of PTEN function could exacerbate
the transformed phenotype and lead to metastatiction of PTEN into the glioblastoma cell line U-87MG
leads to direct dephosphorylation of FAK by PTEN, thus growth.
Outstanding Questionsinhibiting integrin-mediated cell spreading and migra-
tion (Tamura et al., 1999). These functions seem to de- The Pten knockout mouse revealed an essential role for
PTEN during embryogenesis (Di Cristofano et al., 1998;pend on the tyrosine phosphatase activity of PTEN, as
the lipid phosphatase-inactive mutant G129E is able to Suzuki et al., 1998; Podsypanina et al., 1999). Complete
inactivation of the gene results in embryonic lethalityinhibit cell spreading and to dephosphorylate FAK. It
has also been proposed that PTEN is able to bind and between day 6.5 and 9.5 post coitum (probably de-
pending on the mouse genetic background), owing todephosphorylate the p52 isoform of Shc, thus inhibiting
the recruitment of the Grb2 adaptor and the subsequent aberrant differentiation and patterning of the germ lay-
ers. Pten2/2 embryonic stem (ES) cells show profoundactivation of the MAP kinase cascade (Tamura et al.,
1999). By regulating FAK and Shc phosphorylation in alteration in their ability to differentiate in vitro into em-
bryoid bodies, and in vivo when transplanted into synge-response to integrin ligation, PTEN would thus modulate
various aspects of cell adhesion and migration. Although neic and nude recipient mice (Di Cristofano et al., 1998).
Analysis of the mutant embryos showed a poorly orga-the tumor-suppressive functions of PTEN appear to de-
pend only on its lipid phosphatase activity, loss of PTEN nized ectodermal and mesodermal layers, and over-
growth of the cephalic and caudal regions due to aber-tyrosine phosphatase function could contribute to the
invasive phenotype of PTEN2/2 tumor cells. However, no rant patterning (Suzuki et al., 1998). However, it is still
not known which primary differentiation pathway(s)difference in the phosphorylation of FAK was observed
between Pten1/1 and Pten2/2 ES cells (Sun et al., 1999), is deregulated upon loss of PTEN function. It is also
not clear whether aberrant cellular differentiation con-and another group could not reproduce, in U-87MG
cells, either the direct interaction between PTEN and tributes to neoplastic transformation in PTEN mutant
tumors.FAK, or FAK dephosphorylation upon PTEN transfec-
tion, even though the reexpression of PTEN induced Very little is known about the regulation of PTEN ex-
pression and subcellular localization. Loss of a tightboth morphological changes and inhibition of invasion
(Maier et al., 1999). A thorough analysis of this controver- control in transcription, translation, half-life, and local-
ization of PTEN could have a dramatic impact on cellsial issue is clearly a major priority in understanding
the role of PTEN in high-grade and metastatic tumor survival, proliferation, and tumorigenesis. PTEN mRNA
is rapidly downregulated upon TGFb treatment of a hu-biology.
Loss of PTEN Function: A Late Event man keratinocyte tumor cell line (Li and Sun, 1997), but
the biological significance of this regulatory pathway isin Tumorigenesis?
In classic models of neoplastic transformation, a tumor- still unclear. In addition, PTEN contains a three±amino
acid carboxy-terminal region (TKV-COOH) that is poten-suppressor gene harbors a somatic or inherited muta-
tion in one allele, then loss of the other allele results in tially able to bind to PDZ domain±containing proteins.
PDZ domains are often involved in the assembly of multi-a selective proliferative/survival advantage that contrib-
utes to overt malignant transformation. Loss of the sec- protein complexes, so this region might contribute to
controlling PTEN localization and interaction with otherond allele often occurs by deletion of a large chromo-
somal region, resulting in loss of heterozygosity (LOH) proteins, although the deletion of these amino acids has
been reported not to alter the tumor-suppressive activityof polymorphic markers mapping to that region. For this
reason, in most studies on mutations of PTEN in human of PTEN (Georgescu et al., 1999).
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Paramio, J.M., Navarro, M., Segrelles, C., Gomez-Casero, E., andA domain important in regulating the subcellular local-
Jorcano, J.L. (1999). Oncogene 18, 7462±7468.ization of PTEN has been identified through the elucida-
Podsypanina, K., Ellenson, L.H., Nemes, A., Gu, J., Tamura, M.,tion of its crystal structure: PTEN binds to the membrane
Yamada, K.M., Cordon-Cardo, C., Catoretti, G., Fisher, P.E., andphospholipids through a C2 domain. Unlike the C2 do-
Parsons, R. (1999). Proc. Natl. Acad. Sci. USA 96, 1563±1568.
mains of several other signaling proteins, this structure
Stambolic, V., Suzuki, A., de la Pompa, J.L., Brothers, G.M., Mirtsos,
does not require calcium to bind the cell membrane. C., Sasaki, T., Ruland, J., Penninger, J.M., Siderovski, D.P., and
Moreover, the C2 domain is tightly associated with the Mak, T.W. (1998). Cell 95, 29±39.
PTEN phosphatase domain, suggesting that it may also Sun, H., Lesche, R., Li, D.M., Liliental, J., Zhang, H., Gao, J., Gavri-
serve to position the catalytic site correctly with respect lova, N., Mueller, B., Liu, X., and Wu, H. (1999). Proc. Natl. Acad.
Sci. USA 96, 6199±6204.to its substrate. Consistent with this hypothesis, muta-
Suzuki, A., de la Pompa, J.L., Stambolic, V., Elia, A.J., Sasaki, T.,genesis of residues in the C2 domain reduced the tumor-
del Barco Barrantes, I., Ho, A., Wakeham, A., Itie, A., Khoo, W., etsuppressive activity of PTEN without interfering with its
al. (1998). Curr. Biol. 8, 1169±1178.enzymatic activity in vitro (Lee et al., 1999).
Tamura, M., Gu, J., Tran, H., and Yamada, K.M. (1999). J. Natl.One of the most challenging questions to be ad-
Cancer Inst. 91, 1820±1828.dressed in the future is whether additional PTEN sub-
Weng, L.P., Smith, W.M., Dahia, P.L., Ziebold, U., Gil, E., Lees, J.A.,strates exist. Finding such substrates will clarify the
and Eng, C. (1999). Cancer Res. 59, 5808±5814.
extent to which the PTEN and PI3-kinase/Akt pathways
overlap and provide new insights into the function of
PTEN in tumor suppression. In this respect, it is interest-
ing to note that recent genetic studies in Drosophila and
C. elegans underscore the role for PTEN in the insulin
receptor/PI3-kinase pathway, but do not rule out that
PTEN controls PIP-3-independent pathways implicated
in functions other than cell growth/cell death control.
The extensive accomplishments of PTEN research in
just over two years have unraveled a critical role of this
tumor suppressor in the pathogenesis of human cancer.
Despite these important advances, many aspects of
PTEN biology await further clarification. Addressing
these exciting open questions will eventually provide the
basis for novel and more specific strategies for cancer
therapy.
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